ArticleStem cell reports2026
PRDM16 modulates aspects of cell cycle dynamics and maturation in human iPSC-derived cardiomyocytes.
Article in Stem cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deciphering how cardiomyocytes exit proliferation and acquire postnatal maturity is essential for understanding heart development and regenerative potential. We identify PRDM16 as a regulator that influences the balance between proliferation and maturation in human iPSC-derived cardiomyocytes (hiPSC-CMs). Mechanistically, PRDM16 controls proliferative activity by modulating CDK1 and phospho-AKT, two central drivers of cardiomyocyte cell cycle progression. Loss of PRDM16 profoundly disrupts metabolic and structural maturation, yielding abnormal sarcomeric protein ratios and impaired engineered heart tissue function. In contrast, moderate PRDM16 overexpression promotes metabolic rewiring and structural remodeling characteristic of mature cardiomyocytes. These findings support a model in which PRDM16 functions as a context-dependent modulator governing the transition from proliferation to maturation. By demonstrating that transient downregulation favors proliferation while sustained expression drives maturation, our work highlights PRDM16 as both a potential developmental regulator and a therapeutic target for enhancing cardiomyocyte regeneration, cardiac repair, and the functional engineering of human heart tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.